Fce 22250 | CAS#84475-07-0 | antibiotic

MedKoo Cat#: 584402 | Name: Fce 22250

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Fce 22250 is a broad spectrum antibiotic active against Mycobacterium.

Chemical Structure

Fce 22250

CAS#84475-07-0

Theoretical Analysis

MedKoo Cat#: 584402

Name: Fce 22250

CAS#: 84475-07-0

Chemical Formula: C44H58N4O12

Exact Mass: 834.4051

Molecular Weight: 834.96

Elemental Analysis: C, 63.29; H, 7.00; N, 6.71; O, 22.99

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Fce 22250; Fce-22250; Fce22250

IUPAC/Chemical Name

(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,26E)-2,15,17,29-Tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23,27-trioxo-26-{[(2E)-2-(1-piperidinylmethylene)hydrazino]methylene}-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(28),2,4,9,19,21,25(29)-heptaen-13-yl acetate

InChi Key

SRGITGUCGGVOQM-YNQXYWRISA-N

InChi Code

InChI=1S/C44H58N4O12/c1-22-14-13-15-23(2)43(56)47-34-29(20-45-46-21-48-17-11-10-12-18-48)38(53)31-32(39(34)54)37(52)27(6)41-33(31)42(55)44(8,60-41)58-19-16-30(57-9)24(3)40(59-28(7)49)26(5)36(51)25(4)35(22)50/h13-16,19-22,24-26,30,35-36,40,45,50-52,54H,10-12,17-18H2,1-9H3,(H,47,56)/b14-13+,19-16+,23-15+,29-20+,46-21+/t22-,24+,25+,26+,30-,35-,36+,40+,44-/m0/s1

SMILES Code

CC(O[C@@H]([C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(C)/C(NC(/C1=C/N/N=C/N2CCCCC2)=C3O)=O)[C@H](C)[C@@H](OC)/C=C/O[C@](O4)(C)C(C5=C4C(C)=C(O)C3=C5C1=O)=O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 834.96 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Della Bruna C, Ungheri D, Sebben G, Sanfilippo A. Laboratory evaluation of a new long-acting 3-azinomethylrifamycin FCE 22250. J Antibiot (Tokyo). 1985 Jun;38(6):779-86. PubMed PMID: 3839503. 2: Ungheri D, Morvillo E, Sanfilippo A. [Activity of the ansamycins LM 427 and FCE 22250 on atypical mycobacteria in vitro]. G Ital Chemioter. 1983 May-Dec;30(2-3):97-100. Italian. PubMed PMID: 6329872. 3: Zanetti S, Ungheri D, Castellani Pastoris M, Fadda G. Comparative in vitro susceptibility studies of FCE 22250 and rifampicin on Legionella and Chlamydia trachomatis strains. Drugs Exp Clin Res. 1987;13(10):631-4. PubMed PMID: 3428127. 4: Amitani R, Kuze F. [New drugs against tuberculosis and nontuberculous mycobacterial infections: a review]. Kekkaku. 1994 Nov;69(11):711-7. Review. Japanese. PubMed PMID: 7837725. 5: Abeck D, Johnson AP, Alexander F, Korting HC, Ballard RC. In vitro activity of eight antimicrobial agents against non-penicillinase-producing gonococci isolated in Munich. Genitourin Med. 1988 Aug;64(4):233-4. PubMed PMID: 3139546; PubMed Central PMCID: PMC1194222. 6: Dickinson JM, Mitchison DA. In vitro observations on the suitability of new rifamycins for the intermittent chemotherapy of tuberculosis. Tubercle. 1987 Sep;68(3):183-93. PubMed PMID: 2834843. 7: Abeck D, Johnson AP, Dangor Y, Ballard RC. Antibiotic susceptibilities and plasmid profiles of Haemophilus ducreyi isolates from southern Africa. J Antimicrob Chemother. 1988 Oct;22(4):437-44. PubMed PMID: 3264554. 8: Kawahara S. [Chemotherapeutic agents under study]. Nihon Rinsho. 1998 Dec;56(12):3096-9. Review. Japanese. PubMed PMID: 9883617. 9: Vigevani A, Arlandini E, Ballabio M, Franceschi G, Gioia B, Vioglio S. Physico-chemical properties of FCE 22250, 3-(piperidinomethylazinomethyl)rifamycin SV, a new long-acting rifamycin. Farmaco Prat. 1985 May;40(5):131-40. PubMed PMID: 3839192. 10: Liu L, Wang ZY, Li D, Sun SL. [Disposition of 3-(N-piperidinomethylarino)methyl-rifamycin SV (FCE 22250) in rats]. Zhongguo Yao Li Xue Bao. 1991 Jan;12(1):58-62. Chinese. PubMed PMID: 1950587.